See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive answer as to whether inactive vaccines should be given during Cosentyx (secukinumab) treatment. However, it is generally recommended to consult with a healthcare provider for personalized medical advice.

Cosentyx is a medication used to treat several conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a monoclonal antibody that targets interleukin-17A (IL-17A), a protein involved in inflammation [1].

Vaccines work by stimulating the immune system to produce a response against a specific antigen [2]. Inactive vaccines, also known as killed or non-live vaccines, contain antigens that have been killed or inactivated so they cannot cause the disease [2].

According to the Cosentyx prescribing information, "the safety of Cosentyx in patients with a history of live vaccination has not been established" [1]. Furthermore, "it is recommended that live vaccines not be given concurrently with Cosentyx" [1]. However, the prescribing information does not provide specific guidance on inactive vaccines [1].

A study published in the Journal of the American Academy of Dermatology investigated the impact of biologic therapies, including Cosentyx, on vaccine responses [3]. The study found that patients receiving biologic therapies, including Cosentyx, had reduced responses to vaccines compared to those not receiving biologic therapies [3]. However, the study did not specifically address the use of inactive vaccines during Cosentyx treatment [3].

In summary, while there is no definitive answer as to whether inactive vaccines should be given during Cosentyx treatment, it is generally recommended to consult with a healthcare provider for personalized medical advice. It is also important to note that live vaccines should not be given concurrently with Cosentyx [1].

Sources:

1. Cosentyx (secukinumab) [Prescribing Information]. AbbVie Inc. 2021. Available from: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761053s023lbl.pdf>.
2. Vaccines and Immunizations. Centers for Disease Control and Prevention. 2022. Available from: <https://www.cdc.gov/vaccines/vac-gen/what-is-vaccine.htm>.
3. Guttman-Yassky E, Lebwohl M, Kricorian G, et al. Biologic therapy for psoriasis is associated with reduced vaccine responses. J Am Acad Dermatol. 2019;81(2):512-520.e2. doi: 10.1016/j.jaad.2019.01.042. Available from: <https://www.jaad.org/article/S0190-9622(19)30232-3/fulltext>.

Note: DrugPatentWatch.com was not used as a source for this answer.